Similar articles

• Oncogene suppression by small interfering RNAs.

  Heidenreich O. Heidenreich O. Curr Pharm Biotechnol. 2004 Aug;5(4):349-54. doi: 10.2174/1389201043376733. Curr Pharm Biotechnol. 2004. PMID: 15320765 Review.
• RNA-based drugs: from RNA interference to short interfering RNAs.

  Poliseno L, Mercatanti A, Citti L, Rainaldi G. Poliseno L, et al. Curr Pharm Biotechnol. 2004 Aug;5(4):361-8. doi: 10.2174/1389201043376797. Curr Pharm Biotechnol. 2004. PMID: 15320767 Review.
• Multifunctional nanosystems: growing sanguinity in siRNA therapy.

  Badrealam KF, Owais M. Badrealam KF, et al. Int J Nanomedicine. 2014 Apr 10;9:1771-3. doi: 10.2147/IJN.S57440. eCollection 2014. Int J Nanomedicine. 2014. PMID: 24748788 Free PMC article. No abstract available.
• Why RNAi makes sense.

  Hough SR, Wiederholt KA, Burrier AC, Woolf TM, Taylor MF. Hough SR, et al. Nat Biotechnol. 2003 Jul;21(7):731-2. doi: 10.1038/nbt0703-731b. Nat Biotechnol. 2003. PMID: 12833082 No abstract available.
• Dermatological applications of gene silencing RNA technology.

  Slater DN. Slater DN. Br J Dermatol. 2011 May;164(5):939. doi: 10.1111/j.1365-2133.2011.10354.x. Br J Dermatol. 2011. PMID: 21518325 No abstract available.